C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

24 فبراير 2022 06:00:03 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

10 يناير 2022 06:00:02 بحسب Nasdaq GlobeNewswire

C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 يناير 2022 06:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Added to NASDAQ Biotechnology Index

17 ديسمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

10 نوفمبر 2021 15:01:01 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

11 أغسطس 2021 15:02:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma

11 أغسطس 2021 15:01:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

21 يونيو 2021 15:01:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

21 يونيو 2021 07:00:01 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces Pricing of Public Offering

16 يونيو 2021 18:51:25 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Launches Proposed Public Offering

14 يونيو 2021 15:12:23 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies

14 يونيو 2021 07:00:01 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

07 يونيو 2021 06:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies

26 مايو 2021 06:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Appoints Lauren White as Chief Financial Officer

20 مايو 2021 15:01:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

13 مايو 2021 15:01:01 بحسب Nasdaq GlobeNewswire

C4 Therapeutics to Present at Upcoming Investor Conferences

12 مايو 2021 06:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021

10 أبريل 2021 14:05:00 بحسب Nasdaq GlobeNewswire